The pharmaceutical and healthcare industry was always slow in adopting new trends. In my opinion, it was a slow-moving industry due to the necessity of providing safe and practical solutions to patients, which needs accuracy and diligence in all processes.
The Post World War II area - especially the 90s of the last century - was a Golden Age for the industry. Companies like Pfizer, Eli Lilly, Sanofi, Merck, and many others churned out new antibiotics, vaccines, and medications at an astonishing rate that radically changed people’s lives for the better.
One of the effects that the industry created was contributing to the uptake in life expectancy. Before 1900 the average life expectancy was between 30 to 40 years, after World war 2 about 55 years, and in 2021 in many countries is close to 80 years.
Since March 2020, the pharmaceutical industry has faced many challenges and witnessed a major revamp. The pandemic, the digitalization, lockdowns, and disruption of supply chains created a new environment for many sectors, also the pharma industry.
The industry's sheer size makes it essential for anyone involved in healthcare to stay abreast of pharmaceutical industry trends. Multinational healthcare firm Iqvia projects that the global pharmaceutical market will grow to $1.6 trillion by 2025.
To keep up with the development, I asked Bettina Resl, Public Affairs Head Europe Consumer Healthcare at Sanofi, to give an inside perspective on the topic “Trends in the Pharma Industry.”
Speaker in this Episode:
Bettina Resl joined Sanofi, Austria, in May 2017 as Country Head Public Affairs & Patient Advocacy.
From April 2020 to June 2021, she was also responsible for corporate communications and finally took over the position of Public Affairs Head Europe Consumer Healthcare at Sanofi on July 1, 2021.
Resl has 15 years of professional experience in public and political institutions and was a partner at Thierry Politikberatung between 2011 and 2013.
From 2014 onwards, the 41-year-old worked for the US pharmaceutical company AbbVie in government affairs and market access.
From 2008 to 2011, she worked as an advisor for university policy in the cabinet of Science Ministers Johannes Hahn and Beatrix Karl.
Before that, she was a consultant at the Federal Ministry for Health and Women under Maria Rauch-Kallat (2005 to 2007) and a member of parliament for Rauch-Kallat when she rejoined parliament in 2007. She also headed the office of the United Nations Association Austria (2002-2005).
The mother of three children studied political science and Russian at the University of Vienna and attended the master's degree in public health at the Medical University of Vienna. She also completed the political management course in Berlin and the 6th strategic leadership course of the Austrian federal government.
Questions we will discuss:
Collaboration in the Pharmaceutical Industry
The Pharma Value Chain
The Role of Patents
And much more….